VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Deferred Revenue
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Deferred Revenue of -$5.91 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-02-15
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$9.15M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $4.44M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$360.00K.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$839.00K.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for fiscal 2017 was -$5.91M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for fiscal 2016 was -$13.37M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for fiscal 2015 was -$19.24M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in deferred revenue for fiscal 2014 was -$25.53M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$4.71M derived: sum of 2 quarters · filed 2018-02-15 | -$5.07M derived: sum of 3 quarters · filed 2018-02-15 | -$5.91M 10-K · filed 2018-02-15 |
| 2017-09-30 | $4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $4.08M derived: sum of 2 quarters · filed 2017-10-30 | $3.24M 10-Q · filed 2017-10-30 | $69.00K derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | -$360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$1.20M 10-Q · filed 2017-07-28 | -$4.37M derived: sum of 3 quarters · filed 2018-02-15 | -$7.44M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$839.00K 10-Q · filed 2017-04-28 | -$4.01M derived: sum of 2 quarters · filed 2018-02-15 | -$7.08M derived: sum of 3 quarters · filed 2018-02-15 | -$11.40M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$6.24M derived: sum of 2 quarters · filed 2018-02-15 | -$10.56M derived: sum of 3 quarters · filed 2018-02-15 | -$13.37M 10-K · filed 2018-02-15 |
| 2016-09-30 | -$3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | -$7.39M derived: sum of 2 quarters · filed 2017-10-30 | -$10.20M 10-Q · filed 2017-10-30 | -$15.70M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$7.13M 10-Q · filed 2017-07-28 | -$12.62M derived: sum of 3 quarters · filed 2018-02-15 | -$17.07M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$2.81M 10-Q · filed 2017-04-28 | -$8.31M derived: sum of 2 quarters · filed 2018-02-15 | -$12.75M derived: sum of 3 quarters · filed 2018-02-15 | -$16.72M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$9.94M derived: sum of 2 quarters · filed 2018-02-15 | -$13.91M derived: sum of 3 quarters · filed 2018-02-15 | -$19.24M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | -$8.42M derived: sum of 2 quarters · filed 2016-10-31 | -$13.75M 10-Q · filed 2016-10-31 | -$24.20M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | -$9.30M 10-Q · filed 2016-08-01 | -$19.75M derived: sum of 3 quarters · filed 2017-02-23 | -$28.97M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$5.33M 10-Q · filed 2016-05-03 | -$15.78M derived: sum of 2 quarters · filed 2017-02-23 | -$25.00M derived: sum of 3 quarters · filed 2017-02-23 | -$32.62M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$19.66M derived: sum of 2 quarters · filed 2017-02-23 | -$27.29M derived: sum of 3 quarters · filed 2017-02-23 | -$25.53M 10-K · filed 2017-02-23 |
| 2014-09-30 | -$9.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | -$16.84M derived: sum of 2 quarters · filed 2015-10-30 | -$15.09M 10-Q · filed 2015-10-30 | -$52.65M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$7.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | -$5.87M 10-Q · filed 2015-08-04 | -$43.43M derived: sum of 3 quarters · filed 2016-02-16 | -$52.03M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $1.76M 10-Q · filed 2015-05-04 | -$35.81M derived: sum of 2 quarters · filed 2016-02-16 | -$44.41M derived: sum of 3 quarters · filed 2016-02-16 | -$53.28M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | -$37.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$46.17M derived: sum of 2 quarters · filed 2016-02-16 | -$55.03M derived: sum of 3 quarters · filed 2016-02-16 | -$53.01M 10-K · filed 2016-02-16 |
| 2013-09-30 | -$8.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$17.47M derived: sum of 2 quarters · filed 2014-11-06 | -$15.45M 10-Q · filed 2014-11-06 | -$22.57M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$8.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$6.84M 10-Q · filed 2014-07-31 | -$13.96M derived: sum of 3 quarters · filed 2015-02-13 | -$20.40M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $2.02M 10-Q · filed 2014-05-05 | -$5.10M derived: sum of 2 quarters · filed 2015-02-13 | -$11.54M derived: sum of 3 quarters · filed 2015-02-13 | -$20.85M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$13.56M derived: sum of 2 quarters · filed 2015-02-13 | -$22.87M derived: sum of 3 quarters · filed 2015-02-13 | -$39.32M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$6.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$15.75M derived: sum of 2 quarters · filed 2013-11-07 | -$32.20M 10-Q · filed 2013-11-07 | -$50.99M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$9.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | -$25.76M 10-Q · filed 2013-08-02 | -$44.55M derived: sum of 3 quarters · filed 2014-02-11 | -$61.69M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | -$16.45M 10-Q · filed 2013-05-08 | -$35.24M derived: sum of 2 quarters · filed 2014-02-11 | -$52.37M derived: sum of 3 quarters · filed 2014-02-11 | -$71.93M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | -$18.78M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$35.92M derived: sum of 2 quarters · filed 2014-02-11 | -$55.48M derived: sum of 3 quarters · filed 2014-02-11 | -$71.54M 10-K · filed 2014-02-11 |
| 2011-09-30 | -$17.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$36.69M derived: sum of 2 quarters · filed 2012-11-06 | -$52.75M 10-Q · filed 2012-11-06 | -$95.02M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$19.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$35.61M 10-Q · filed 2012-08-08 | -$77.89M derived: sum of 3 quarters · filed 2013-03-01 | -$74.44M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$16.06M 10-Q · filed 2012-05-10 | -$58.33M derived: sum of 2 quarters · filed 2013-03-01 | -$54.89M derived: sum of 3 quarters · filed 2013-03-01 | -$66.45M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$42.27M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$38.83M derived: sum of 2 quarters · filed 2013-03-01 | -$50.40M derived: sum of 3 quarters · filed 2013-03-01 | -$65.86M 10-K · filed 2013-03-01 |
| 2010-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$8.12M derived: sum of 2 quarters · filed 2011-11-03 | -$23.59M 10-Q · filed 2011-11-03 | -$42.60M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | -$11.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | -$27.04M 10-Q · filed 2011-08-09 | -$46.04M derived: sum of 3 quarters · filed 2012-02-22 | $42.73M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | -$15.47M 10-Q · filed 2011-05-06 | -$34.47M derived: sum of 2 quarters · filed 2012-02-22 | $54.30M derived: sum of 3 quarters · filed 2012-02-22 | $45.90M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $69.77M derived: sum of 2 quarters · filed 2012-02-22 | $61.37M derived: sum of 3 quarters · filed 2012-02-22 | $53.06M 10-K · filed 2012-02-22 |
| 2009-09-30 | $88.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $80.37M derived: sum of 2 quarters · filed 2010-10-28 | $72.06M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | -$8.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | -$16.71M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | -$8.31M 10-Q · filed 2010-05-03 | |||
| 2008-12-31 | $115.09M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |